# Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

> clinical trial · VERIFIED · 2026-07-28

Status: RECRUITING · Sponsor: University of California, San Diego · Condition: Basal Cell Carcinoma

- Company: University of California, San Diego
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06624475

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.